Suzana Meira Ribeiro
Universidade Católica Dom Bosco
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Suzana Meira Ribeiro.
Scientific Reports | 2016
Marlon Henrique Cardoso; Suzana Meira Ribeiro; Diego O. Nolasco; César de la Fuente-Núñez; Mário R. Felício; Sónia Gonçalves; Carolina O. Matos; Luciano M. Lião; Nuno C. Santos; Robert E. W. Hancock; Octavio L. Franco; Ludovico Migliolo
Due to the growing concern about antibiotic-resistant microbial infections, increasing support has been given to new drug discovery programs. A promising alternative to counter bacterial infections includes the antimicrobial peptides (AMPs), which have emerged as model molecules for rational design strategies. Here we focused on the study of Pa-MAP 1.9, a rationally designed AMP derived from the polar fish Pleuronectes americanus. Pa-MAP 1.9 was active against Gram-negative planktonic bacteria and biofilms, without being cytotoxic to mammalian cells. By using AFM, leakage assays, CD spectroscopy and in silico tools, we found that Pa-MAP 1.9 may be acting both on intracellular targets and on the bacterial surface, also being more efficient at interacting with anionic LUVs mimicking Gram-negative bacterial surface, where this peptide adopts α-helical conformations, than cholesterol-enriched LUVs mimicking mammalian cells. Thus, as bacteria present varied physiological features that favor antibiotic-resistance, Pa-MAP 1.9 could be a promising candidate in the development of tools against infections caused by pathogenic bacteria.
Scientific Reports | 2016
Osmar N. Silva; Eliane S. F. Alves; César de la Fuente-Núñez; Suzana Meira Ribeiro; Santi M. Mandal; Diana Gaspar; Ana Salomé Veiga; Miguel A. R. B. Castanho; Cesar A.S. Andrade; Jéssica M. Nascimento; Isabel C. M. Fensterseifer; William F. Porto; José R. Corrêa; Robert E. W. Hancock; Suresh Korpole; Aline L. de Oliveira; Luciano M. Lião; Octavio L. Franco
Clavanins is a class of peptides (23aa) histidine-rich, free of post-translational modifications. Clavanins have been studied largely for their ability to disrupt bacterial membranes. In the present study, the interaction of clavanin A with membranes was assessed by dynamic light scattering, zeta potential and permeabilization assays. We observed through those assays that clavanin A lysis bacterial cells at concentrations corresponding to its MIC. Further, the structure and function of clavanin A was investigated. To better understand how clavanin interacted with bacteria, its NMR structure was elucidated. The solution state NMR structure of clavanin A in the presence of TFE-d3 indicated an α-helical conformation. Secondary structures, based on circular dichroism measurements in anionic sodium dodecyl sulfate (SDS) and TFE (2,2,2-trifluorethanol), in silico lipid-peptide docking and molecular simulations with lipids DPPC and DOPC revealed that clavanin A can adopt a variety of folds, possibly influencing its different functions. Microcalorimetry assays revealed that clavanin A was capable of discriminating between different lipids. Finally, clavanin A was found to eradicate bacterial biofilms representing a previously unrecognized function.
The Journal of Antibiotics | 2017
Thais Bergamin Lima; Osmar N. Silva; Keyla C. de Almeida; Suzana Meira Ribeiro; Dielle de Oliveira Motta; Simone Maria-Neto; Michelle Brizolla Lara; Carlos Roberto Souza Filho; Alicia Simalie Ombredane; Celio de Faria Junior; Nádia Skorupa Parachin; Beatriz Simas Magalhães; Octavio L. Franco
Enterobacter cloacae is a Gram-negative bacterium associated with high morbidity and mortality in intensive care patients due to its resistance to multiple antibiotics. Currently, therapy against multi-resistant bacteria consists of using colistin, in spite of its toxic effects at higher concentrations. In this context, colistin-resistant E. cloacae strains were challenged with lower levels of colistin combined with other antibiotics to reduce colistin-associated side effects. Colistin-resistant E. cloacae (ATCC 49141) strains were generated by serial propagation in subinhibitory colistin concentrations. After this, three colistin-resistant and three nonresistant replicates were isolated. The identity of all the strains was confirmed by MALDI-TOF MS, VITEK 2 and MicroScan analysis. Furthermore, cross-resistance to other antibiotics was checked by disk diffusion and automated systems. The synergistic effects of the combined use of colistin and chloramphenicol were observed via the broth microdilution checkerboard method. First, data here reported showed that all strains presented intrinsic resistance to penicillin, cephalosporin (except fourth generation), monobactam, and some associations of penicillin and β-lactamase inhibitors. Moreover, a chloramphenicol and colistin combination was capable of inhibiting the induced colistin-resistant strains as well as two colistin-resistant clinical strains. Furthermore, no cytotoxic effect was observed by using such concentrations. In summary, the data reported here showed for the first time the possible therapeutic use of colistin–chloramphenicol for infections caused by colistin-resistant E. cloacae.
Future Microbiology | 2016
Suzana Meira Ribeiro; Marlon Henrique Cardoso; Elizabete de Souza Cândido; Octavio L. Franco
The ability of pathogenic bacteria to aggregate and form biofilm represents a great problem for public health, since they present extracellular components that encase these micro-organisms, making them more resistant to antibiotics and host immune attack. This may become worse when antibiotic-resistant bacterial strains form biofilms. However, antibiofilm screens with different compounds may reveal potential therapies to prevent/treat biofilm infections. Here, we focused on Klebsiella pneumoniae, an opportunistic bacterium that causes different types of infections, including in the bloodstream, meninges, lungs, urinary system and at surgical sites. We also highlight aspects involved in the formation and maintenance of K. pneumoniae biofilms, as well as resistance and the emergence of new trends to combat this health challenge.
Handbook of Biologically Active Peptides (Second Edition) | 2013
Suzana Meira Ribeiro; William F. Porto; Osmar N. Silva; Marcelo de Oliveira Santos; Simoni Campos Dias; Octávio L. Franco
A large number of peptides isolated from different plant species seem to play an important role in plant defense against fungi. The antifungal activities of these compounds have been associated with interaction with components from walls, membranes, or nuclei of fungal cells. According to this view, antifungal peptides may cause physiological, morphological, and molecular disorders and in some cases kill the fungal cell, being dependent on several factors, including chemical and structural properties from peptides and genetic aspects of fungal host species, which consequently may determine susceptibility or resistance to peptides. In this chapter, the structural and functional properties of multiple plant antifungal peptide families, including defensins, cyclotides, and several others, will be analyzed, relating structural parameters with fungicidal activities. Moreover, the potential biotechnological use of these molecules for the treatment of fungal infections in humans and mainly in the protection of economically important crops will also be examined.
Antimicrobial Agents and Chemotherapy | 2017
Camila G. Freitas; Stella Maris de Freitas Lima; Mirna S. Freire; Ana Paula C. Cantuária; Nelson Gomes de Oliveira Junior; Tatiane S. Santos; Jéssica S. Folha; Suzana Meira Ribeiro; Simoni Campos Dias; Taia Maria Berto Rezende; Patrícia Albuquerque; André Moraes Nicola; César de la Fuente-Núñez; Robert E. W. Hancock; Octavio L. Franco; Maria Sueli Soares Felipe
ABSTRACT Fungal Candida species are commensals present in the mammalian skin and mucous membranes. Candida spp. are capable of breaching the epithelial barrier of immunocompromised patients with neutrophil and cell-mediated immune dysfunctions and can also disseminate to multiple organs through the bloodstream. Here we examined the action of innate defense regulator 1018 (IDR-1018), a 12-amino-acid-residue peptide derived from bovine bactenecin (Bac2A): IDR-1018 showed weak antifungal and antibiofilm activity against a Candida albicans laboratory strain (ATCC 10231) and a clinical isolate (CI) (MICs of 32 and 64 μg · ml−1, respectively), while 8-fold lower concentrations led to dissolution of the fungal cells from preformed biofilms. IDR-1018 at 128 μg · ml−1 was not hemolytic when tested against murine red blood cells and also has not shown a cytotoxic effect on murine monocyte RAW 264.7 and primary murine macrophage cells at the tested concentrations. IDR-1018 modulated the cytokine profile during challenge of murine bone marrow-derived macrophages with heat-killed C. albicans (HKCA) antigens by increasing monocyte chemoattractant protein 1 (MCP-1) and interleukin-10 (IL-10) levels, while suppressing tumor necrosis factor alpha (TNF-α), IL-1β, IL-6, and IL-12 levels. Mice treated with IDR-1018 at 10 mg · kg−1 of body weight had an increased survival rate in the candidemia model compared with phosphate-buffered saline (PBS)-treated mice, together with a diminished kidney fungal burden. Thus, IDR-1018 was able to protect against murine experimental candidemia and has the potential as an adjunctive therapy.
Scientific Reports | 2016
Marlon Henrique Cardoso; Suzana Meira Ribeiro; Diego O. Nolasco; César de la Fuente-Núñez; Mário R. Felício; Sónia Gonçalves; Carolina O. Matos; Luciano M. Lião; N. C. Santos; Robert E. W. Hancock; Octavio L. Franco; Ludovico Migliolo
Scientific Reports 6: Article number: 2138510.1038/srep21385; published online: February 26 2016; updated: July 20 2016 In this Article, there is a typographical error in the Results section. “Pa-MAP 1.9 (NH2-LAAKLTKAATKLTAALTKLAAALT-COOH) was designed …” should read: “Pa-MAP 1.9 (NH2-LAAKLTKAATKLTAALTKLAAALTAAAT-COOH) was designed …”
Nature Communications | 2018
William F. Porto; Luz N. Irazazabal; Eliane S. F. Alves; Suzana Meira Ribeiro; Carolina O. Matos; Állan S. Pires; Isabel C. M. Fensterseifer; Vívian de Jesus Miranda; Evan F. Haney; Vincent Humblot; Marcelo D. T. Torres; Robert E. W. Hancock; Luciano M. Lião; Ali Ladram; Timothy K. Lu; César de la Fuente-Núñez; Octávio L. Franco
Archive | 2017
Isabel C. M. Fensterseifer; Octávio L. Franco; Osmar N. Silva; Suzana Meira Ribeiro
Medical research archives | 2017
Suzana Meira Ribeiro; Alinne Pereira de Castro; Octávio Luiz Franco